Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Leerink Partners Analyst Says

Amgen (NASDAQ:AMGN) had its price objective upped by analysts at Leerink Partners from $305.00 to $355.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the medical research company’s stock. Leerink Partners’ price target suggests a potential downside of 3.48% from the company’s current price.

A number of other analysts have also issued reports on the company. HSBC reaffirmed a “buy” rating and issued a $425.00 target price on shares of Amgen in a report on Wednesday, December 10th. UBS Group raised their price objective on shares of Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. The Goldman Sachs Group upped their target price on shares of Amgen from $400.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Morgan Stanley reduced their price target on shares of Amgen from $329.00 to $304.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. Finally, Argus boosted their price objective on shares of Amgen from $310.00 to $360.00 and gave the stock a “buy” rating in a report on Tuesday, December 30th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $347.65.

Amgen Price Performance

NASDAQ AMGN opened at $367.80 on Wednesday. Amgen has a 1 year low of $261.43 and a 1 year high of $374.90. The company has a fifty day simple moving average of $333.66 and a 200 day simple moving average of $310.84. The company has a current ratio of 1.14, a quick ratio of 0.99 and a debt-to-equity ratio of 5.78. The company has a market cap of $198.05 billion, a P/E ratio of 25.85, a P/E/G ratio of 3.20 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts predict that Amgen will post 20.62 EPS for the current year.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the sale, the senior vice president directly owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the sale, the senior vice president owned 7,082 shares in the company, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 10,908 shares of company stock valued at $3,674,966 over the last quarter. 0.76% of the stock is owned by company insiders.

Institutional Trading of Amgen

Institutional investors have recently bought and sold shares of the stock. Anfield Capital Management LLC lifted its holdings in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the period. Dogwood Wealth Management LLC increased its position in shares of Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares in the last quarter. Board of the Pension Protection Fund acquired a new stake in shares of Amgen during the 4th quarter worth about $26,000. Legacy Investment Solutions LLC acquired a new position in Amgen in the second quarter valued at about $27,000. Finally, Evelyn Partners Investment Management LLP acquired a new position in Amgen in the second quarter valued at about $32,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 results beat Street estimates and management issued a robust 2026 outlook, driven by double‑digit revenue and EPS growth and strong new‑product uptake — a primary driver of the rally. Amgen Q4 results beat Street estimates
• Positive Sentiment: Several brokerages raised price targets (notably Goldman Sachs to $415 and RBC/Leerink upgrades), lending credibility to upside expectations and supporting institutional buying interest. Goldman Sachs adjusts price target on Amgen
• Positive Sentiment: Momentum indicators and flow show Amgen near 52‑week highs with reports of institutional accumulation, reinforcing sentiment that the company’s growth trajectory is being re‑rated. Amgen Stock Hits 52-Week Highs: Buy Signal?
• Neutral Sentiment: Amgen reported completion of postmarketing work on IMLYGIC’s melanoma safety study and updates on the FORTITUDE‑301 trial; these procedural milestones reduce uncertainty but are unlikely to move the needle until detailed data or regulatory actions follow. IMLYGIC safety study reaches completion
• Neutral Sentiment: Analyst coverage is mixed: some firms reiterate holds or lower relative targets even as others are bullish, creating a split narrative on valuation vs. execution risk. Analyst: new-product uptake offset by legacy erosion
• Negative Sentiment: CVS Health will remove Amgen and Lilly bone‑disease treatments from some preferred drug lists effective April 1, substituting lower‑cost alternatives — a clear near‑term sales headwind for affected products and a reason for investor caution. CVS to drop Amgen and Lilly bone disease treatments

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.